Siguazodan

Siguazodan

SCHEMBL5170622

CNC(=NC#N)Nc1ccc(C2=NNC(=O)CC2C)cc1

nearest known ligand 0.70

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.70
ALDH1A1 P00352 2/20 0.70
CYP1A2 P05177 1/20 0.70
CYP3A4 P08684 1/20 0.70
ALOX15 P16050 1/20 0.70
TSHR P16473 1/20 0.70
MAPK1 P28482 1/20 0.70
LMNA P02545 1/20 0.70
BLM P54132 1/20 0.70
NPSR1 Q6W5P4 1/20 0.70
PDE3B Q13370 16/20 0.64
PDE3A Q14432 16/20 0.64
TNNC1 P63316 1/20 0.64
SMN1; SMN2 Q16637 2/20 0.53
MAPT P10636 1/20 0.53
PDE4A P27815 2/20 0.47
PDE4B Q07343 2/20 0.47
PDE4C Q08493 2/20 0.47
PDE4D Q08499 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Siguazodan SCHEMBL6558367 1.00 KDM4E (0.70) KDM4EALDH1A1CYP1A2CYP3A4ALOX15
SCHEMBL10652569 0.88 KDM4E (0.66) KDM4EALDH1A1CYP1A2CYP3A4ALOX15
SCHEMBL10762684 0.88 KDM4E (0.66) KDM4EALDH1A1CYP1A2CYP3A4ALOX15
SCHEMBL10653471 0.88 KDM4E (0.66) KDM4EALDH1A1CYP1A2CYP3A4ALOX15
SCHEMBL10651830 0.87 KDM4E (0.67) KDM4EALDH1A1CYP1A2CYP3A4ALOX15
SCHEMBL10765447 0.86 KDM4E (0.64) KDM4EALDH1A1CYP1A2CYP3A4ALOX15
SCHEMBL10764400 0.86 KDM4E (0.64) KDM4EALDH1A1CYP1A2CYP3A4ALOX15
SCHEMBL10618267 0.86 KDM4E (0.76) KDM4EALDH1A1CYP1A2CYP3A4ALOX15
SCHEMBL10764489 0.86 KDM4E (0.63) KDM4EALDH1A1CYP1A2CYP3A4ALOX15
SCHEMBL10652516 0.85 KDM4E (0.62) KDM4EALDH1A1CYP1A2CYP3A4ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1176960-B1 SYNERGISTIC COMBINATION COMPRISING ROFLUMILAST AND A PDE-3 INHIBITOR ALTANA PHARMA AG (DE) 2004-09-29 EP claimed
EP-0150937-B1 DIHYDROPYRIDAZINONES SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1988-09-14 EP claimed
EP-0150937-A2 Dihydropyridazinones SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1985-08-07 EP claimed
WO-1985003076-A1 DIHYDROPYRIDAZINONES SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1985-07-18 WO claimed
JP-1113317-A None JP disclosed
EP-3334404-A1 COMPOSITIONS AND METHODS FOR CANCER EXPRESSING PDE3A OR SLFN12 The Broad Institute, Inc. (US) 2018-06-20 EP disclosed
WO-2017027854-A1 COMPOSITIONS AND METHODS FOR CANCER EXPRESSING PDE3A OR SLFN12 THE BROAD INSTITUTE, INC. (US) 2017-02-16 WO disclosed
EP-0946183-B1 USE OF PYRIDAZINONE OR PHOSPHINE OXIDE COMPOUNDS TO TREAT OR PREVENT CARDIAC ARRHYTHMIA MERCK & CO INC (US) 2007-05-02 EP disclosed
EP-1176960-B1 SYNERGISTIC COMBINATION COMPRISING ROFLUMILAST AND A PDE-3 INHIBITOR ALTANA PHARMA AG (DE) 2004-09-29 EP disclosed
JP-H01113317-A ANTIARRHYTHMIC MEDICINE SMITH KLINE LTD 1989-05-02 JP disclosed
EP-0150937-B1 DIHYDROPYRIDAZINONES SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1988-09-14 EP disclosed
EP-0150937-A2 Dihydropyridazinones SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1985-08-07 EP disclosed
WO-1985003076-A1 DIHYDROPYRIDAZINONES SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1985-07-18 WO disclosed